Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Hum Reprod. 2017 Sep 1;32(9):1846-1854. doi: 10.1093/humrep/dex237.
Is pre-treatment alcohol and caffeine intake associated with infertility treatment outcomes among women undergoing ART?
Low to moderate alcohol and caffeine intakes in the year prior to infertility treatment were not related to ART outcomes.
Alcohol and caffeine intake have been found to be associated with infertility in some studies. Nevertheless, data on their relation with outcomes of infertility treatments are scarce and inconsistent.
STUDY DESIGN, SIZE, DURATION: We included 300 women (493 ART cycles) from the Environment and Reproductive Health Study, an ongoing cohort study (2006-2016).
PARTICIPANTS/MATERIALS, SETTING, METHODS: Pre-treatment intakes of alcohol and caffeine were assessed retrospectively using a validated food frequency questionnaire. Intermediate and clinical endpoints of ART were abstracted from electronic medical records. Generalized linear mixed models with random intercepts to account for multiple ART cycles per woman were used to evaluate the association with ART outcomes adjusting for age, BMI, smoking status, infertility diagnosis, protocol type, race, dietary patterns, and calories, vitamin B12 and folate intake.
Median (range) pre-treatment alcohol and caffeine intakes were 5.6 (0.0-85.8) g/day and 124.9 (0.3-642.2) mg/day, respectively. The adjusted percentage of initiated cycles resulting in live birth (95% CI) for women in increasing categories of pre-treatment alcohol intake was 34% (20, 52%) for non-consumers, 46% (36, 57%) for 0.1-6 g/day, 41% (29, 53%) for 6.1-12 g/day, 42% (31, 55%) for 12.1-24 g/day, and 41% (22, 63%) for >24 g/day (P, trend = 0.87). The adjusted percentage of cycles resulting in live birth (95% CI) for women in increasing categories of caffeine intake was 46% (36-57%) for <50 mg/day, 44% (29, 60%) for 50.1-100 mg/day, 42% (31, 53%) for 100.1-200 mg/day, 40% (28, 53%) for 200.1-300 mg/day and 40% (21, 63%) for >300 mg/day (P, trend = 0.34). When specific types of alcoholic and caffeinated beverages were evaluated, no relations with ART treatment outcomes were observed.
LIMITATIONS, REASONS FOR CAUTION: Residual confounding by other diet and lifestyle factors cannot be ruled out owing to the observational nature of this study. It is also unclear how generalizable these results are to women who are conceiving without the assistance of ART.
Our results provide reassurance that low to moderate intakes of alcohol (e.g. ≤12 g/day) and caffeine (e.g. <200 mg/day) in the year prior to infertility treatment initiation do not have an adverse effect on intermediate or clinical outcomes of ART.
STUDY FUNDING/COMPETING INTEREST(S): The authors are supported by National Institutes of Health (NIH) grants ES022955, R01ES009718, R01ES000002, P30DK46200 and L50-HD085359. No conflicts of interest to declare.
NCT00011713.
在接受 ART 治疗的女性中,治疗前的酒精和咖啡因摄入与不孕治疗结果有关吗?
在接受不孕治疗前的一年中,低至中度的酒精和咖啡因摄入与 ART 结果无关。
一些研究发现,酒精和咖啡因的摄入与不孕有关。然而,关于它们与不孕治疗结果的关系的数据仍然很少且不一致。
研究设计、规模、持续时间:我们纳入了来自环境与生殖健康研究的 300 名女性(493 个 ART 周期),这是一个正在进行的队列研究(2006-2016 年)。
参与者/材料、设置、方法:使用经过验证的食物频率问卷回顾性评估治疗前的酒精和咖啡因摄入量。从电子病历中提取 ART 的中间和临床终点。使用广义线性混合模型,具有随机截距以考虑每个女性的多个 ART 周期,在调整年龄、BMI、吸烟状况、不孕诊断、方案类型、种族、饮食模式和卡路里、维生素 B12 和叶酸摄入后,评估与 ART 结果的关联。
治疗前酒精和咖啡因摄入量的中位数(范围)分别为 5.6(0.0-85.8)g/天和 124.9(0.3-642.2)mg/天。在递增的治疗前酒精摄入量类别中,起始周期的活产百分比(95%CI)为非消费者的 34%(20,52%),0.1-6 g/天的 46%(36,57%),6.1-12 g/天的 41%(29,53%),12.1-24 g/天的 42%(31,55%),和 >24 g/天的 41%(22,63%)(P,趋势=0.87)。在递增的咖啡因摄入量类别中,活产周期的百分比(95%CI)为<50 mg/天的 46%(36-57%),50.1-100 mg/天的 44%(29,60%),100.1-200 mg/天的 42%(31,53%),200.1-300 mg/天的 40%(28,53%),和 >300 mg/天的 40%(21,63%)(P,趋势=0.34)。当评估特定类型的含酒精和含咖啡因的饮料时,没有观察到与 ART 治疗结果的关系。
局限性、谨慎的原因:由于这项研究的观察性质,仍然不能排除其他饮食和生活方式因素的残余混杂。目前还不清楚这些结果在多大程度上适用于未经 ART 帮助而怀孕的女性。
我们的研究结果提供了保证,即在不孕治疗开始前的一年中,低至中度的酒精(例如,≤12 g/天)和咖啡因(例如,<200 mg/天)摄入不会对 ART 的中间或临床结果产生不利影响。
研究资金/利益冲突:作者得到美国国立卫生研究院(NIH)拨款 ES022955、R01ES009718、R01ES000002、P30DK46200 和 L50-HD085359 的支持。没有利益冲突的声明。
NCT00011713。